KD Logo

BTIG Research’s latest rating for AKBA stock

Akebia Therapeutics Inc.’s filing revealed that its CEO and President Butler John P. unloaded Company’s shares for reported $73581.0 on Feb 29 ’24. In the deal valued at $1.58 per share,46,570 shares were sold. As a result of this transaction, Butler John P. now holds 2,044,580 shares worth roughly $2.64 million.

Then, Dahan Michel sold 8,661 shares, generating $13,684 in total proceeds. Upon selling the shares at $1.58, the SVP, Chief Operating Officer now owns 706,932 shares.

Before that, Burke Steven Keith sold 7,169 shares. Akebia Therapeutics Inc. shares valued at $11,327 were divested by the SVP, Chief Medical Officer at a price of $1.58 per share. As a result of the transaction, Burke Steven Keith now holds 695,840 shares, worth roughly $0.9 million.

A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who increased its forecast for the stock in late August from “a Neutral” to “a Buy”. Piper Sandler also remained covering AKBA and has increased its forecast on May 31, 2023 with a “an Overweight” recommendation from previously “Neutral” rating. Piper Sandler revised its rating on March 31, 2022. It rated AKBA as “a Neutral” which previously was an “an Overweight”.

Price Performance Review of AKBA

On Monday, Akebia Therapeutics Inc. [NASDAQ:AKBA] saw its stock jump 6.61% to $1.29. Over the last five days, the stock has lost -13.42%. Akebia Therapeutics Inc. shares have risen nearly 4.03% since the year began. Nevertheless, the stocks have risen 21.70% over the past one year. While a 52-week high of $2.48 was reached on 03/28/24, a 52-week low of $0.78 was recorded on 05/09/24. SMA at 50 days reached $1.5352, while 200 days put it at $1.3263. A total of 2.41 million shares were traded, compared to the trading of 2.32 million shares in the previous session.

Levels Of Support And Resistance For AKBA Stock

The 24-hour chart illustrates a support level at 1.2200, which if violated will result in even more drops to 1.1500. On the upside, there is a resistance level at 1.3300. A further resistance level may holdings at 1.3700. The Relative Strength Index (RSI) on the 14-day chart is 42.78, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0555, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 50.94%. Stochastics %K at 46.54% indicates the stock is a holding.

Most Popular

[the_ad id="945"]